| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1035873781 |
| P356 | DOI | 10.1007/S00125-004-1648-4 |
| P698 | PubMed publication ID | 15660260 |
| P5875 | ResearchGate publication ID | 8071709 |
| P50 | author | Michael Jonathan Davies | Q39746881 |
| P2093 | author name string | R T Dean | |
| B E Brown | |||
| P2860 | cites work | Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 | Q25938983 |
| Biochemistry and molecular cell biology of diabetic complications | Q28131781 | ||
| Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition | Q28625661 | ||
| Role of lysines in mediating interaction of modified low density lipoproteins with the scavenger receptor of human monocyte macrophages | Q28678300 | ||
| THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM | Q29391553 | ||
| Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria | Q29616614 | ||
| Glycoxidation and lipid peroxidation of low-density lipoprotein can synergistically enhance atherogenesis | Q31874092 | ||
| The pathogenesis of atherosclerosis (first of two parts) | Q33492794 | ||
| d-alpha-tocopherol inhibition of vascular smooth muscle cell proliferation occurs at physiological concentrations, correlates with protein kinase C inhibition, and is independent of its antioxidant properties | Q33654586 | ||
| Nonoxidative modifications of lipoproteins in atherogenesis | Q33711770 | ||
| Glycoxidation and lipoxidation in atherogenesis | Q34006261 | ||
| The oxidative modification hypothesis of atherogenesis: an overview | Q34006328 | ||
| Abnormalities in apo B-containing lipoproteins in diabetes and atherosclerosis | Q34176669 | ||
| Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway | Q34229420 | ||
| Advanced protein glycosylation in diabetes and aging | Q34298835 | ||
| Identification in human atherosclerotic lesions of GA-pyridine, a novel structure derived from glycolaldehyde-modified proteins | Q34528130 | ||
| The macrophage foam cell as a target for therapeutic intervention | Q34986351 | ||
| Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts | Q35024062 | ||
| The role of lipid peroxidation and antioxidants in oxidative modification of LDL. | Q35379559 | ||
| Specificity of receptor-mediated recognition of malondialdehyde-modified low density lipoproteins | Q36286282 | ||
| Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end products | Q36502603 | ||
| Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. | Q37363088 | ||
| Glycolaldehyde, a reactive intermediate for advanced glycation end products, plays an important role in the generation of an active ligand for the macrophage scavenger receptor | Q40851598 | ||
| Effect of methylglyoxal on the physico-chemical and biological properties of low-density lipoprotein. | Q40998272 | ||
| Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification--a role in pathogenesis and antiproliferative chemotherapy. | Q41148677 | ||
| Modification of lipoproteins in diabetes | Q41155220 | ||
| Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis | Q41367560 | ||
| Degradation by cultured fibroblasts and macrophages of unmodified and 1,2-cyclohexanedione-modified low-density lipoprotein from normal and homozygous familial hypercholesterolaemic subjects | Q42000024 | ||
| Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose | Q42070713 | ||
| Glycation and glycoxidation of low-density lipoproteins by glucose and low-molecular mass aldehydes. Formation of modified and oxidized particles | Q44550064 | ||
| Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor | Q49165106 | ||
| Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. | Q53913926 | ||
| The intracellular storage and turnover of apolipoprotein B of oxidized LDL in macrophages. | Q54268090 | ||
| Induction of Macrophage Lysosomal Enzyme Secretion by Agents Acting at the Plasma Membrane | Q66980496 | ||
| Stimulation of cholesteryl ester synthesis in human monocyte-derived macrophages by low-density lipoproteins from type 1 (insulin-dependent) diabetic patients: the influence of non-enzymatic glycosylation of low-density lipoproteins | Q68671546 | ||
| Erythrocyte glyoxalase activity in genetically obese (ob/ob) and streptozotocin diabetic mice | Q69452117 | ||
| Oxidative modification of glycated low density lipoprotein in the presence of iron | Q70175198 | ||
| Glycosylation of low-density lipoprotein enhances cholesteryl ester synthesis in human monocyte-derived macrophages | Q70385571 | ||
| Glycation accelerates the oxidation of low density lipoprotein by copper ions | Q70885663 | ||
| N.epsilon.-(Carboxymethyl)lysine Is a Dominant Advanced Glycation End Product (AGE) Antigen in Tissue Proteins | Q72030217 | ||
| Development of the atherosclerotic core region. Chemical and ultrastructural analysis of microdissected atherosclerotic lesions from human aorta | Q72102957 | ||
| Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction | Q72190978 | ||
| Apolipoprotein A-I-mediated efflux of sterols from oxidized LDL-loaded macrophages | Q72235686 | ||
| Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin | Q72352188 | ||
| Inhibition of protein kinase C activity and vascular smooth muscle cell growth by d-alpha-tocopherol | Q72364959 | ||
| A method for defining the stages of low-density lipoprotein oxidation by the separation of cholesterol- and cholesteryl ester-oxidation products using HPLC | Q72604244 | ||
| Does superoxide radical have a role in macrophage-mediated oxidative modification of LDL? | Q72961338 | ||
| Lipoprotein glycation and its metabolic consequences | Q73484267 | ||
| Increase in three alpha,beta-dicarbonyl compound levels in human uremic plasma: specific in vivo determination of intermediates in advanced Maillard reaction | Q74583225 | ||
| Chemical modification of proteins by methylglyoxal | Q77659598 | ||
| Role of oxidative stress in diabetic complications: a new perspective on an old paradigm | Q77804864 | ||
| Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease | Q77910765 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 361-369 | |
| P577 | publication date | 2005-01-20 | |
| P1433 | published in | Diabetologia | Q5270140 |
| P1476 | title | Glycation of low-density lipoproteins by methylglyoxal and glycolaldehyde gives rise to the in vitro formation of lipid-laden cells | |
| P478 | volume | 48 |
| Q51747235 | AGE-RAGE Stress, Stressors, and Antistressors in Health and Disease. |
| Q36887564 | Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. |
| Q36716474 | Aldehyde metabolism in the cardiovascular system. |
| Q61800652 | Apolipoprotein A-I enhances insulin-dependent and insulin-independent glucose uptake by skeletal muscle |
| Q30431517 | Apolipoprotein A-I glycation by glucose and reactive aldehydes alters phospholipid affinity but not cholesterol export from lipid-laden macrophages |
| Q30360076 | Beneficial effect of low ethanol intake on the cardiovascular system: possible biochemical mechanisms |
| Q34576122 | Carnosine and its constituents inhibit glycation of low-density lipoproteins that promotes foam cell formation in vitro |
| Q92156071 | Dietary Glycotoxins Impair Hepatic Lipidemic Profile in Diet-Induced Obese Rats Causing Hepatic Oxidative Stress and Insulin Resistance |
| Q35195762 | Effect of exposure of human monocyte-derived macrophages to high, versus normal, glucose on subsequent lipid accumulation from glycated and acetylated low-density lipoproteins |
| Q40137109 | Glycation of low-density lipoprotein results in the time-dependent accumulation of cholesteryl esters and apolipoprotein B-100 protein in primary human monocyte-derived macrophages |
| Q53563811 | Glycoxidised LDL isolated from subjects with impaired glucose tolerance increases CD36 and peroxisome proliferator-activator receptor gamma gene expression in macrophages. |
| Q40319157 | Hydrazine compounds inhibit glycation of low-density lipoproteins and prevent the in vitro formation of model foam cells from glycolaldehyde-modified low-density lipoproteins. |
| Q38765114 | Identification and detoxification of glycolaldehyde, an unattended bioethanol fermentation inhibitor. |
| Q58803250 | Influenza A virus infection dysregulates the expression of microRNA-22 and its targets; CD147 and HDAC4, in epithelium of asthmatics |
| Q38619292 | Low-density lipoprotein modified by myeloperoxidase oxidants induces endothelial dysfunction |
| Q39255171 | Myeloperoxidase-derived oxidants modify apolipoprotein A-I and generate dysfunctional high-density lipoproteins: comparison of hypothiocyanous acid (HOSCN) with hypochlorous acid (HOCl). |
| Q64985998 | Oxidative Modification of LDL by Various Physicochemical Techniques: Its Probable Role in Diabetes Coupled with CVDs. |
| Q34137628 | Pathological aspects of lipid peroxidation. |
| Q38197358 | Reducing methylglyoxal as a therapeutic target for diabetic heart disease |
| Q36229648 | Role of Myeloperoxidase Oxidants in the Modulation of Cellular Lysosomal Enzyme Function: A Contributing Factor to Macrophage Dysfunction in Atherosclerosis? |
| Q85103261 | Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes |
| Q79537656 | The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase |
| Q38394355 | The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases |
Search more.